Granted Patent
B2
US 12,697,251 · App. 17/892,822 · Granted Aug 4, 2026
Pressurized goggle for intraocular pressure modification
Inventors:
John Berdahl (Sioux Falls, SD); Richard Cornelius (Wayzata, MN); Vance Michael Thompson (Sioux Falls, SD)
Assignee:
John Berdahl
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Assemblies and methods for modifying an intraocular pressure of a patient's one or both eyes are disclosed. The assemblies and methods can be used to treat, inhibit, or prevent ocular conditions such as glaucoma, high intraocular pressure, optic disc edema, idiopathic intracranial hypertension, zero-gravity induced papilledema, and other optic pressure related conditions. An assembly can include a goggle including at least one cavity, a pump in fluid communication with the at least one cavity, and a control mechanism. The control mechanism can be operatively coupled to the pump and can maintain a target pressure or target pressure range in the at least one cavity, which, when the assembly is worn by a patient, is the area between a patient's eye(s) and wall surfaces of the goggle. Controlling the pressure over the outer surfaces of the patient's eye(s) can drive a desired change in the intraocular pressure of the eye(s).
Claims (23)
1 . A pressure assembly to adjust cavity fluid pressure in a cavity to treat an eye condition of a patient based on a determined translaminar pressure gradient (TPG), the TPG being a pressure difference between biosensor-measured intraocular pressure (IOP) and separately and independently biosensor-measured cerebrospinal fluid pressure (CSFP), the cavity defined by an enclosure sized and shaped to fit over a patient eye without contacting a surface of the patient eye, the pressure assembly comprising:
control circuitry, configured to receive the biosensor-measured IOP and the separately and independently biosensor-measured CSFP and, based thereupon, to determine the TPG associated with the patient eye, and
a pressure source, configured to receive a control signal from the control circuitry and adjust the cavity fluid pressure toward a target IOP level in the patient eye based on the biosensor-measured IOP to equalize the determined TPG associated with the patient eye.
2 . The assembly of claim 1 , wherein the cavity fluid pressure is in a range of less than 0 mmHg gauge to about −40 mmHg gauge to treat glaucoma.
3 . The assembly of claim 1 , wherein the cavity fluid pressure is in a range of about −5 mmHg gauge to about −20 mmHg gauge.
4 . The assembly of claim 1 , wherein the cavity fluid pressure is in a range of greater than 0 mmHg gauge to about 40 mmHg gauge to treat ocular edema.
5 . The assembly of claim 1 , wherein the cavity fluid pressure is configured to vary over time.
6 . The assembly of claim 5 , wherein a cavity fluid pressure sequence is configured to vary based on a diurnal cycle.
7 . The assembly of claim 5 , wherein the cavity fluid pressure is configured to vary as a sequence over time.
8 . The assembly of claim 5 , wherein the cavity fluid pressure is varied as a sequence over time to increase a flow of an eye fluid through a trabecular meshwork in the patient eye.
9 . The assembly of claim 1 , wherein the cavity pressure is applied for a duration of time selected to treat the eye condition.
10 . The assembly of claim 9 , wherein the duration of time includes the duration being long enough to allow axonal transport to resume.
11 . The assembly of claim 1 , wherein the pressure control mechanism includes a pressure source controlled by control circuitry to establish the cavity fluid pressure in a range of less than 0 mmHg gauge to about −40 mmHg gauge to treat glaucoma.
12 . The assembly of claim 1 , wherein the pressure control mechanism includes a pressure source controlled by control circuitry to establish the cavity fluid pressure in a range of about −5 mmHg gauge to about −20 mmHg gauge.
13 . The assembly of claim 1 , wherein the pressure control mechanism includes a pressure source controlled by control circuitry to establish the cavity fluid pressure in a range of greater than 0 mmHg gauge to about 40 mmHg gauge to treat ocular edema.
14 . The assembly of claim 1 , wherein the pressure control mechanism includes a pressure source controlled by control circuitry to establish the cavity fluid pressure being configured to vary over time.
15 . The assembly of claim 14 , wherein the pressure control mechanism includes a pressure source controlled by control circuitry to establish a cavity fluid pressure sequence that is configured to vary based on a diurnal cycle.
16 . The assembly of claim 14 , wherein the pressure control mechanism includes a pressure source controlled by control circuitry to establish the cavity fluid pressure is configured to vary as a sequence over time.
17 . The assembly of claim 14 , wherein the pressure control mechanism includes a pressure source controlled by control circuitry to establish the cavity fluid pressure that is varied as a sequence over time to increase a flow of an eye fluid through a trabecular meshwork in the patient eye.
18 . The assembly of claim 1 , wherein the pressure control mechanism includes a pressure source controlled by control circuitry to establish the cavity pressure that is applied for a duration of time selected to treat the eye condition.
19 . The assembly of claim 18 , wherein the duration of time includes the duration required to allow axonal transport to resume.
20 . A pressure assembly to adjust fluid pressure in a cavity to treat an eye condition of a patient, based on a determined translaminar pressure gradient (TPG), the TPG being a pressure difference between biosensor-measured intraocular pressure (IOP) in the patient eye and separately and independently biosensor-measured cerebrospinal fluid pressure (CSFP) in the patient, the cavity defined by an enclosure sized and shaped to fit over a patient eye without contacting a surface of the patient eye, the pressure assembly comprising:
a pressure control mechanism including control circuitry configured to receive the biosensor-measured IOP and the separately and independently biosensor-measured CSFP and, based thereupon, to determine the TPG associated with the patient eye and to provide a control signal based thereupon to adjust the cavity fluid pressure toward a target IOP level in the patient eye based on the biosensor-measured IOP to equalize the determined TPG.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 1, 2022
From: CORNELIUS, RICHARD
To: DR. JOHN BERDAHL
Reel/Frame 061613/0424 →
NUNC PRO TUNC ASSIGNMENT
Recorded Nov 1, 2022
From: THOMPSON, VANCE MICHAEL
To: DR. JOHN BERDAHL
Reel/Frame 061613/0551 →
Continuity (9)
Continuation
15912872
· Mar 6, 2018
Continuation
15688043
· Aug 28, 2017
Continuation
15688016
· Aug 28, 2017
Provisional Application
61609078
· Mar 9, 2012
Related Publication
20230043903A1
· Feb 9, 2023
References Cited (356)
US 2555636A
· Felts et al.
· 1951
[cited by applicant]
US 3545260A
· Lichtenstein et al.
· 1970
[cited by applicant]
US 4305399A
· Beale
· 1981
[cited by applicant]
US 4387707A
· Polikoff
· 1983
[cited by applicant]
US 4604087A
· Joseph et al.
· 1986
[cited by applicant]
US 4724843A
· Fisher
· 1988
[cited by applicant]
US 4907595A
· Strauss
· 1990
[cited by applicant]
US 5201312A
· Schenck et al.
· 1993
[cited by applicant]
US 5300020A
· L'Esperance, Jr.
· 1994
[cited by applicant]
US 5338291A
· Speckman et al.
· 1994
[cited by applicant]
US 5523808A
· Kohayakawa
· 1996
[cited by applicant]
US 5601548A
· Smith et al.
· 1997
[cited by applicant]
US 5625426A
· Liu
· 1997
[cited by applicant]
US 5927281A
· Monteleone et al.
· 1999
[cited by applicant]
US 5951477A
· Ragaluskals et al.
· 1999
[cited by applicant]
US 6093147A
· Kontiola
· 2000
[cited by applicant]
US 6129682A
· Borchert et al.
· 2000
[cited by applicant]
US 6307302B1
· Toda
· 2001
[cited by applicant]
US 6315727B1
· Coleman et al.
· 2001
[cited by applicant]
US 6390989B1
· Denninghoff
· 2002
[cited by applicant]
US 6673014B2
· Badchi et al.
· 2004
[cited by applicant]
US 6814966B1
· Wax et al.
· 2004
[cited by applicant]
US 7122007B2
· Querfurth
· 2006
[cited by applicant]
US 7137952B2
· Leonardi
· 2006
[cited by applicant]
US 7331666B2
· Swab et al.
· 2008
[cited by applicant]
US 7512436B2
· Petty et al.
· 2009
[cited by applicant]
US 7850638B2
· Theodore
· 2010
[cited by applicant]
US 8408204B2
· Lurie
· 2013
[cited by applicant]
US 8939906B2
· Huang et al.
· 2015
[cited by applicant]
US 8998810B2
· Kontiola et al.
· 2015
[cited by applicant]
US 9125724B2
· Berdahl et al.
· 2015
[cited by applicant]
US 9168172B1
· Berdahl
· 2015
[cited by applicant]
US 9173564B2
· Choo et al.
· 2015
[cited by applicant]
US 9498380B2
· Berdahl et al.
· 2016
[cited by applicant]
US 20020124843A1
· Skiba et al.
· 2002
[cited by applicant]
US 20020193675A1
· Rathjen
· 2002
[cited by applicant]
US 20030078486A1
· Klein et al.
· 2003
[cited by applicant]
US 20040111050A1
· Smedley et al.
· 2004
[cited by applicant]
US 20080171953A1
· Mische
· 2008
[cited by applicant]
US 20080306429A1
· Shields et al.
· 2008
[cited by applicant]
US 20090043365A1
· Friedland et al.
· 2009
[cited by applicant]
US 20120222201A1
· Dondero
· 2012
[cited by applicant]
US 20130072828A1
· Sweis et al.
· 2013
[cited by applicant]
US 20130141690A1
· Taylor et al.
· 2013
[cited by applicant]
US 20130215376A1
· Guo et al.
· 2013
[cited by applicant]
US 20130218145A1
· Belkin et al.
· 2013
[cited by applicant]
US 20210068657A1
· Berdahl et al.
· 2021
[cited by applicant]
AU 2016311449B2
· 2019
[cited by applicant]
AU 2019202196A1
· 2019
[cited by applicant]
AU 2019202196B2
· 2020
[cited by applicant]
CN 102264277A
· 2011
[cited by applicant]
CN 103479326A
· 2014
[cited by applicant]
CN 203989163U
· 2014
[cited by applicant]
CN 108135738A
· 2018
[cited by applicant]
CN 113038869
· 2021
[cited by applicant]
CN 113842266
· 2021
[cited by applicant]
DE 19730735A1
· 1999
[cited by applicant]
IN 202117009018
· 2021
[cited by applicant]
JP H03193037A
· 1991
[cited by applicant]
JP 2007301215A
· 2007
[cited by applicant]
JP 2013255791A
· 2013
[cited by applicant]
JP 2018527143A
· 2018
[cited by applicant]
JP 2021180879
· 2021
[cited by applicant]
JP 2021532920
· 2021
[cited by applicant]
KR 102136640B1
· 2020
[cited by applicant]
WO WO2007012008A2
· 2007
[cited by applicant]
WO WO2007136993A1
· 2007
[cited by applicant]
WO WO2007139927A1
· 2007
[cited by applicant]
WO WO2010006180A1
· 2010
[cited by applicant]
WO 2016071428
· 2016
[cited by applicant]
WO WO2017035406A2
· 2017
[cited by applicant]
WO WO2017035406A3
· 2017
[cited by applicant]
WO 2017156050
· 2017
[cited by applicant]
WO WO2018174835A1
· 2018
[cited by applicant]
WO 2020033736
· 2020
[cited by applicant]
WO 2021053452
· 2021
[cited by applicant]
Journal of Ophthalmology. Evaluation of Cerebrospinal Fluid Pressure by a Formula and Its Role in the Pathogenesis of Glaucoma. 2019. 2019:1840481.
[cited by examiner]
“Mexican Application Serial No. MX a 2021 001497, Response filed Jun. 25, 2021 to Office Action mailed May 10, 2021”, w o English claims, 136 pgs.
[cited by applicant]
“Korean Application Serial No. 10-2020-7020680, Response filed Jul. 22, 2021 to Final Office Action mailed Apr. 23, 2021”, w English claims, 12 pgs.
[cited by applicant]
“Japanese Application Serial No. 2021-505948, Response filed Jul. 25, 2022 to Notification of Reasons for Refusal mailed May 10, 2022”, w English claims, 9 pgs.
[cited by applicant]
Berdahl, J. P., “The translaminar pressure gradient in sustained zero gravity, idiopathic intracranial hypertension, and glaucoma”, PubMed 79(6), (Dec. 2012), 1 pg.
[cited by applicant]
Digre, Kathleen, “Not so benign intracranial hypertension”, MBJ, 326(7390), (Mar. 22, 2003), 4 pgs.
[cited by applicant]
Fleischman, David, “The role of cerebrospinal fluid pressure in glaucoma and other ophthalmic diseases: A review”, Saudi Journal of Ophthalmology, 27, (2013), 97-106.
[cited by applicant]
Goldman, Robert M., “The Effects of Oscillating Inversion on Systemic Blood Pressure, Pulse Intraocular Pressure, and Central Retinal Arterial Pressure”, The Physician and Sportsmedicine, vol. 13, No. 3, (Mar. 1985), 93…
[cited by applicant]
Huberman, Andrew, “Managing Glaucoma: Beyond Intraocular Pressure. 2011”, Review of Opthalmology, [Online]. Retrieved from the Internet: URL: : http: www.reviewofophthalmology.com continuing_educationlabviewtest lessoni…
[cited by applicant]
Jacks, A. S., “Spontaneous retinal venous pulsation: aetiology and significance”, J Neurol Neurosurg Psychiatry; 74, [Online]. Retrieved from the Internet: URL:www.jnnp.com, (2002), 7-9.
[cited by applicant]
Luo, “Ocular blood flow autoregulation mechanisms and methods”, Eye Center, Renmin Hospital of Wuhan University, Wuhan, China; vol. 2015, (Oct. 21, 2015), 8 pgs.
[cited by applicant]
Muenster, Stefan, “The Ability of Nitric Oxide to Lower Intraocular Pressure Is Dependent on Guanylyl Cyclase”, Investigative Ophthalmology and Visual Science, vol. 58, No. 11, (Sep. 2017), 4826-4835.
[cited by applicant]
Parsa, C F, “Spontaneous venous pulsations should be monitored during glaucoma therapy”, Br J Ophthalmol, 86 (10), (Oct. 2002), 1187.
[cited by applicant]
Sajjadi, “The Relation between Intracranial and Intraocular Pressures: Study of 50 Patients”, Ann Neurol, (2006), 867-870.
[cited by applicant]
Samuelson, T W, “Intracranial pressure may play significant role in glaucoma”, Ocular Surgery News US Edition, (Oct. 25, 2008), 3 pgs.
[cited by applicant]
Siaudvytyte, Lina, “Update in intracranial pressure evaluation methods and translaminar pressure gradient role in glaucoma”, ACTA Opththmalologica, 93, (2015), 9-15.
[cited by applicant]
Wuthrich, U. W., “Postural change and intraocular pressure in glaucomatous eyes”, Brit. J. Ophthal. 60, (1976), 111-114.
[cited by applicant]
Xie, Xiaobin, “Noninvasive intracranial pressure estimation by orbital subarachnoid space measurement: the Beijing Intracranial and Intraocular Pressure (iCOP) study”, Critical Care, 17:R162, [Online]. Retrieved from th…
[cited by applicant]
U.S. Appl. No. 15/754,723 U.S. Pat. No. 10,842,376, filed Feb. 23, 2018, Eye-Related Intrabody Pressure Identification and Modification.
[cited by applicant]
U.S. Appl. No. 17/077,205, filed Oct. 22, 2020, Eye-Related Intrabody Pressure Identification and Modification.
[cited by applicant]
U.S. Appl. No. 13/790,048 U.S. Pat. No. 9,125,724, filed Mar. 8, 2013, Intraocular Pressure Modification.
[cited by applicant]
U.S. Appl. No. 14/800,018 U.S. Pat. No. 9,498,380, filed Jul. 15, 2015, Intraocular Pressure Modification.
[cited by applicant]
U.S. Appl. No. 15/688,016 U.S. Pat. No. 10,709,605, filed Aug. 28, 2017, Eye Monitoring and Pressurization Systems.
[cited by applicant]
U.S. Appl. No. 15/345,053 U.S. Pat. No. 11,497,650, filed Nov. 7, 2016, Pressurized Goggle for Physiological Monitoring or Intraocular Pressure Modification.
[cited by applicant]
U.S. Appl. No. 15/688,043 U.S. Pat. No. 10,154,926, filed Aug. 28, 2017, Methods of Using Eye Monitoring and Pressurization Systems.
[cited by applicant]
U.S. Appl. No. 15/912,872 U.S. Pat. No. 10,940,041, filed Mar. 6, 2018, Eye Cavity Pressure Treatment Using IOP or CSF.
[cited by applicant]
U.S. Appl. No. 17/142,304 U.S. Pat. No. 11,478,379, filed Jan. 6, 2021, Pressurized Goggle for Intraocular Pressure Modifcation.
[cited by applicant]
“U.S. Appl. No. 13/790,048, Final Office Action mailed Feb. 5, 2015”, 13 pgs.
[cited by applicant]
“U.S. Appl. No. 13/790,048, Non Final Office Action mailed Jun. 24, 2014”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 13/790,048, Notice of Allowance mailed May 4, 2015”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 13/790,048, Response filed Apr. 2, 2015 to Final Office Action mailed Feb. 5, 2015”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 13/790,048, Response filed Sep. 24, 2014 to Non Final Office Action mailed Jun. 24, 2014”, 16 pgs.
[cited by applicant]
“U.S. Appl. No. 14/800,018, Examiner Interview Summary mailed Mar. 2, 2016”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 14/800,018, Non Final Office Action mailed Sep. 28, 2015”, 15 pgs.
[cited by applicant]
“U.S. Appl. No. 14/800,018, Notice of Allowance mailed Jul. 20, 2016”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 14/800,018, Preliminary Amendment filed Jul. 28, 2015”, 5 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Advisory Action mailed Oct. 14, 2020”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Advisory Action mailed Dec. 2, 2019”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Final Office Action mailed Mar. 30, 2022”, 17 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Final Office Action mailed Jul. 24, 2020”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Final Office Action mailed Aug. 22, 2019”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Non Final Office Action mailed Jan. 13, 2020”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Non Final Office Action mailed Feb. 15, 2019”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Non Final Office Action mailed May 25, 2021”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Preliminary Amendment filed Nov. 16, 2016”, 5 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Response filed Apr. 13, 2020 to Non Final Office Action mailed Jan. 13, 2020”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Response filed Sep. 23, 2020 to Final Office Action mailed Jul. 24, 2020”, 10 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Response filed Oct. 22, 2019 to Final Office Action mailed Aug. 22, 2019”, 10 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Response filed May 13, 2019 to Non Final Office Action mailed Feb. 15, 2019”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Supplemental Preliminary Amendment filed Aug. 21, 2017”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Advisory Action mailed Jul. 25, 2018”, 4 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Corrected Notice of Allowability mailed Jun. 15, 2020”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Examiner Interview Summary mailed Nov. 25, 2019”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Examiner Interview Summary mailed Dec. 31, 2018”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Final Office Action mailed Mar. 25, 2019”.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Final Office Action mailed May 15, 2018”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Non Final Office Action mailed Aug. 29, 2019”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Non Final Office Action mailed Oct. 5, 2018”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Non Final Office Action mailed Oct. 20, 2017”, 16 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Notice of Allowance mailed Feb. 20, 2020”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Preliminary Amendment filed Aug. 29, 2017”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Response filed Jan. 16, 2018 to Non Final Office Action mailed Oct. 20, 2017”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Response filed May 28, 2019 to Final Office Action mailed Mar. 25, 2019”, 10 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Response filed Jun. 12, 2018 to Final Office Action mailed May 15, 2018”, 10 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Response filed Aug. 15, 2018 to Advisory Action mailed Jul. 25, 2018”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Response filed Nov. 19, 2019 to Non Final Office Action mailed Aug. 29, 2019”, 10 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Response filed Dec. 31, 2018 to Non Final Office Action mailed Oct. 5, 2018”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,043, Corrected Notice of Allowability mailed Sep. 13, 2018”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,043, Corrected Notice of Allowability mailed Sep. 28, 2018”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,043, Corrected Notice of Allowability mailed Nov. 20, 2018”, 2 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,043, Non Final Office Action mailed Mar. 15, 2018”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,043, Notice of Allowance mailed Jul. 16, 2018”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,043, Preliminary Amendment filed Aug. 29, 2017”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,043, Response filed Jun. 15, 2018 to Non Final Office Action mailed Mar. 15, 2018”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 15/754,723, Non Final Office Action mailed Apr. 17, 2020”, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 15/754,723, Notice of Allowance mailed Jul. 29, 2020”, 5 pgs.
[cited by applicant]
“U.S. Appl. No. 15/754,723, Preliminary Amendment filed Feb. 23, 2018”, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 15/754,723, Response filed Jul. 15, 2020 to Non Final Office Action mailed Apr. 17, 2020”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 15/754,723, Supplemental Notice of Allowability mailed Sep. 10, 2020”, 2 pgs.
[cited by applicant]
“U.S. Appl. No. 15/754,723, Supplemental Notice of Allowability mailed Oct. 21, 2020”, 2 pgs.
[cited by applicant]
“U.S. Appl. No. 15/754,723, Supplimental Preliminary Amendment filed Nov. 15, 2018”, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, 312 Amendment filed Jan. 5, 2021”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Advisory Action mailed Mar. 11, 2020”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Corrected Notice of Allowability mailed Feb. 5, 2021”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Corrected Notice of Allowability mailed Feb. 12, 2021”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Examiner Interview Summary mailed Jul. 30, 2020”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Examiner Interview Summary mailed Aug. 30, 2019”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Final Office Action mailed Nov. 28, 2018”, 14 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Final Office Action mailed Dec. 12, 2019”, 13 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Non Final Office Action mailed Apr. 30, 2020”, 17 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Non Final Office Action mailed Jun. 6, 2019”, 13 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Non Final Office Action mailed Jun. 8, 2018”, 13 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Notice of Allowance mailed Oct. 5, 2020”, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Response filed Jan. 4, 2019 to Final Office Action mailed Nov. 28, 2018”, 10 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Response filed Feb. 12, 2020 to Final Office Action mailed Dec. 12, 2019”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Response filed Mar. 20, 2020 to Advisory Action mailed Mar. 11, 2020”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Response filed Jul. 9, 2018 to Non Final Office Action mailed Jun. 8, 2018”, 15 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Response filed Jul. 30, 2020 to Non Final Office Action mailed Apr. 30, 2020”, 10 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Response filed Sep. 6, 2019 to Non-Final Office Action mailed Jun. 6, 2019”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 17/077,205, Preliminary Amendment filed Nov. 25, 2020”, 6 pgs.
[cited by applicant]
“U.S. Appl. No. 17/142,304, Advisory Action mailed Nov. 23, 2021”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 17/142,304, Corrected Notice of Allowability mailed Oct. 3, 2022”, 4 pgs.
[cited by applicant]
“U.S. Appl. No. 17/142,304, Examiner Interview Summary mailed Apr. 19, 2022”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 17/142,304, Examiner Interview Summary mailed Dec. 16, 2021”, 2 pgs.
[cited by applicant]
“U.S. Appl. No. 17/142,304, Final Office Action mailed Aug. 13, 2021”, 10 pgs.
[cited by applicant]
“U.S. Appl. No. 17/142,304, Non Final Office Action mailed Jan. 20, 2022”, 13 pgs.
[cited by applicant]
“U.S. Appl. No. 17/142,304, Non Final Office Action mailed Mar. 16, 2021”, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 17/142,304, Notice of Allowance mailed May 22, 2022”, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 17/142,304, Notice of Allowance mailed May 25, 2022”, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 17/142,304, Notice of Non-Compliant Amendment mailed Jun. 18, 2021”, 2 pgs.
[cited by applicant]
“U.S. Appl. No. 17/142,304, Response filed Apr. 19, 2022 to Non Final Office Action mailed Jan. 20, 2022”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 17/142,304, Response filed Jun. 14, 2021 to Non Final Office Action mailed Mar. 16, 2021”, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 17/142,304, Response filed Jun. 28, 2021 to Notice of Non-Compliant Amendment mailed Jun. 18, 2021”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 17/142,304, Response filed Oct. 12, 2021 to Final Office Action mailed Aug. 13, 2021”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 14/800,018 Response filed Jan. 15, 2016 to Non-Final Office Action mailed Sep. 28, 2015”, 20 pgs.
[cited by applicant]
“Australian Application Serial No. 2016311449, First Examination Report mailed Jul. 27, 2018”, 4 pgs.
[cited by applicant]
“Australian Application Serial No. 2019202196, First Examination Report mailed Apr. 22, 2020”, 5 pgs.
[cited by applicant]
“Australian Application Serial No. 2019202196, Response filed Aug. 19, 2020 to First Examination Report mailed Apr. 22, 2020”, 19 pgs.
[cited by applicant]
“Australian Application Serial No. 2020286245, First Examination Report mailed Apr. 8, 2022”, 4 pgs.
[cited by applicant]
“Biosensor”, Merriam-Webster dictionary, [Online]. Retrieved from the Internet: <https://www.merriam-webster.com/dictionary/biosensor>, (Jan. 6, 2020), 2 pgs.
[cited by applicant]
“Brazilian Application Serial No. 1120180038385, Office Action mailed Jun. 24, 2020”, w/ English Translation, 5 pgs.
[cited by applicant]
“Brazilian Application Serial No. 1120180038385, Response filed Oct. 5, 2020 to Office Action mailed Jun. 24, 2020”, w/ English Claims, 129 pgs.
[cited by applicant]
“Canadian Application Serial No. 2,998,477, Examiner's Rule 30(2) Requisition mailed Oct. 5, 2018”, 3 pgs.
[cited by applicant]
“Canadian Application Serial No. 2,998,477, Office Action mailed Feb. 17, 2020”, 6 pgs.
[cited by applicant]
“Canadian Application Serial No. 2,998,477, Office Action mailed Jun. 25, 2019”, 3 pgs.
[cited by applicant]
“Canadian Application Serial No. 2,998,477, Office Action mailed Aug. 7, 2020”, 6 pgs.
[cited by applicant]
“Canadian Application Serial No. 2,998,477, Response Filed Mar. 18, 2019 to Examiner's Rule 30(2) Requisition mailed Oct. 5, 2018”, 23 pgs.
[cited by applicant]
“Canadian Application Serial No. 2,998,477, Response filed Jun. 9, 2020 to Office Action mailed Feb. 17, 2020”, 18 pgs.
[cited by applicant]
“Canadian Application Serial No. 2,998,477, Response filed Nov. 9, 2020 to Office Action mailed Aug. 7, 2020”, 12 pgs.
[cited by applicant]
“Canadian Application Serial No. 2,998,477, Response filed Dec. 9, 2019 to Office Action mailed Jun. 25, 2019”, 19 pgs.
[cited by applicant]
“Cataract Surgery to Lower Intraocular Pressure”, Middle East African Journal of Ophthalmology, 16 (3), (Sep. 2009), 1-5.
[cited by applicant]
“Chinese Application Serial No. 201680056279.2, Office Action mailed Feb. 19, 2021”, w/English Translation, 21 pgs.
[cited by applicant]
“Chinese Application Serial No. 201680056279.2, Office Action mailed May 22, 2020”, w/ English Translation, 19 pgs.
[cited by applicant]
“Chinese Application Serial No. 201680056279.2, Office Action mailed Sep. 12, 2019”, w/ English translation, 21 pgs.
[cited by applicant]
“Chinese Application Serial No. 201680056279.2, Response filed Jan. 16, 2020 to Office Action mailed Sep. 12, 2019”, w/ English Claims, 18 pgs.
[cited by applicant]
“Chinese Application Serial No. 201680056279.2, Response filed Sep. 27, 2020 to Office Action mailed May 22, 2020”, w/ English Claims, 19 pgs.
[cited by applicant]
“European Application Serial No. 16763632.3, Communication Pursuant to Article 94(3) EPC mailed Mar. 26, 2020”, 4 pgs.
[cited by applicant]
“European Application Serial No. 16763632.3, Communication Pursuant to Article 94(3) EPC mailed Apr. 4, 2019”, 5 pgs.
[cited by applicant]
“European Application Serial No. 16763632.3, Communication Pursuant to Article 94(3) EPC mailed Sep. 28, 2020”, 5 pgs.
[cited by applicant]
“European Application Serial No. 16763632.3, Communication Pursuant to Article 94(3) EPC mailed Oct. 18, 2019”, 4 pgs.
[cited by applicant]
“European Application Serial No. 16763632.3, Response filed Feb. 27, 2020 to Communication Pursuant to Article 94(3) EPC mailed Oct. 18, 2019”, 11 pgs.
[cited by applicant]
“European Application Serial No. 16763632.3, Response filed Apr. 8, 2021 to Communication Pursuant to Article 94(3) EPC mailed Sep. 28, 2020”, 19 pgs.
[cited by applicant]
“European Application Serial No. 16763632.3, Response filed Jul. 22, 2020 to Communication Pursuant to Article 94(3) EPC mailed Mar. 26, 2020”, 14 pgs.
[cited by applicant]
“European Application Serial No. 16763632.3, Response Filed Aug. 14, 2019 to Communication Pursuant to Article 94(3) EPC mailed Apr. 4, 2019”, 15 pgs.
[cited by applicant]
“European Application Serial No. 16763632.3, Response filed Nov. 1, 2018 to Communication Pursuant to Rules 161(1) and 162 EPC mailed Apr. 25, 2018”, w/ English Claims, 11 pgs.
[cited by applicant]
“Eye-Related Intrabody Pressure Identification and Modification”, (Oct. 28, 2019), 3.
[cited by applicant]
“Indian Applicaiton Serial No. 201817010073, First Examination Report mailed Dec. 11, 2020”, w/ English Translation, 7 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2016/048784, International Preliminary Report on Patentability mailed Mar. 8, 2018”, 12 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2016/048784, International Search Report mailed Mar. 21, 2017”, 9 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2016/048784, Invitation to Pay Additional Fees and Partial Search Report mailed Nov. 28, 2016”, 7 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2016/048784, Written Opinion mailed Mar. 21, 2017”, 10 pgs.
[cited by applicant]
“Japanese Application Serial No. 2018-529509, Examiners Decision of Final Refusal mailed Apr. 6, 2021”, w/ English Translation, 7 pgs.
[cited by applicant]
“Japanese Application Serial No. 2018-529509, Notification of Reasons for Refusal mailed Aug. 11, 20020”, w/ English translation, 9 pgs.
[cited by applicant]
“Japanese Application Serial No. 2018-529509, Notification of Reasons for Refusal mailed Dec. 15, 2020”, w/ English translation, 8 pgs.
[cited by applicant]
“Japanese Application Serial No. 2018-529509, Response filed Mar. 5, 2021 to Notification of Reasons for Refusal mailed Dec. 15, 2020”, w/ English claims, 8 pgs.
[cited by applicant]
“Japanese Application Serial No. 2018-529509, Response filed Nov. 11, 2020 to Notification of Reasons for Refusal mailed Aug. 11, 2020”, w/ English Claims, 7 pgs.
[cited by applicant]
“Korean Application Serial No. 10-2018-7008191, Final Office Action mailed Jan. 23, 2020”, w/ English Translation, 5 pgs.
[cited by applicant]
“Korean Application Serial No. 10-2018-7008191, Notice of Preliminary Rejection mailed Jul. 10, 2019”, w/English Translation, 15 pgs.
[cited by applicant]
“Korean Application Serial No. 10-2018-7008191, Response filed Mar. 25, 2020 to Final Office Action mailed Jan. 23, 2020”, w/ English Claims, 12 pgs.
[cited by applicant]
“Korean Application Serial No. 10-2018-7008191, Response Filed Sep. 4, 2019 to Notice of Preliminary Rejection mailed Jul. 10, 2019”, w/English Claims, 26 pgs.
[cited by applicant]
“Korean Application Serial No. 10-2020-7020680, Final Office Action mailed Apr. 23, 2021”, w/English Translation, 10 pgs.
[cited by applicant]
“Korean Application Serial No. 10-2020-7020680, Notice of Preliminary Rejection mailed Oct. 5, 2020”, w/ English Translation, 9 pgs.
[cited by applicant]
“Korean Application Serial No. 10-2020-7020680, Response filed Dec. 7, 20 to Notice of Preliminary Rejection mailed Oct. 5, 20”, w/ English claims, 8 pgs.
[cited by applicant]
Alexander, David J., et al., “Risk of Spaceflight-Induced Intracranial Hypertension and Vision Alterations”, Evidence Report—Version 1.0, (Jul. 12, 2012), 109 pgs.
[cited by applicant]
Allin, David, et al., “Laboratory Testing of the Pressio Intracranial Pressure Monitor”, Neurosurgery, vol. 62, vol. 5, [Online]. Retrieved from the Internet: <URL: www.neurosurgery-online.com, (May 2008), 1158-1161.
[cited by applicant]
Araci, Ismail E., “An implantable microfuidic device for self-monitoring of intraocular pressure”, nature medicine, vol. 20, No. 9—Technical Reports, (Sep. 2014), 1074-1080.
[cited by applicant]
Berdahl, et al., “Cerebrospinal fluid pressure is decreased in primary open-angle glaucoma”, Ophthalmology 115(5), (May 2008), 763-768.
[cited by applicant]
Berdahl, John P., et al., “Body Mass Index Has a Linear Relationship with Cerebrospinal Fluid Pressure”, IOVS, vol. 53, No. 3, (Mar. 2012), 1422-1427.
[cited by applicant]
Berdahl, John, “Cerebrospinal Fluid Pressure and Glaucoma”, Glaucoma Today, (Oct. 2009), 14-18.
[cited by applicant]
Berdahl, John P., et al., “Intracranial pressure and glaucoma”, Current Opinion in Ophthalmology 21-, (2010), 106-111.
[cited by applicant]
Berdahl, John P., et al., “Intracranial Pressure in Primary Open Angle Glaucoma, Normal Tension Glaucoma, and Ocluar Hypertension: A Case-Control Study”, IOVS, vol. 49, No. 12, (Dec. 2008), 5412-5418.
[cited by applicant]
Berdahl, John P., “Recovery of Corneal Hysteresis after Reduction of Intraocular Pressure in Chronic Primary Angle-Closure Glaucoma”, American Journal of Ophthalmology—Correspondence, (Oct. 2009), 623-624.
[cited by applicant]
Berdahl, John P., “Systemic Parameters Associated With Cerebrospinal Fluid Pressure”, J Glaucoma, vol. 22, No. 5, Suppl 1, [Online]. Retrieved from the Internet: <URL: www.glaucomajournal.com, (Jul. 2013), S17-S18.
[cited by applicant]
Berdahl, John P., “The translaminar pressure gradient in sustained zero gravity, idiopathic inracranial hypertension and glaucoma”, Medical Hypotheses 79, (2012), 719-724.
[cited by applicant]
Costa, Vital P., et al., “Ocular perfusion pressure in glaucoma”, Acta Ophthalmologica, (2014), e252-e266.
[cited by applicant]
Fleischman, David, et al., “Cerebrospinal Fluid Pressure Decreases with Older Age”, PLOS One, vol. 7, Issue 12, [Online]. Retrieved from the Internet: <URL: www.plosone.org, (Dec. 2012), 1-9.
[cited by applicant]
Fleischman, David, et al., “Increasing intraocular pressure as treatment for papilledema”, Experimental Eye Research 115, (2013), 278.
[cited by applicant]
Goel, Manik, et al., “Aqueous Humor Dynamics: A Review”, The Open Ophthalmology Journal, [Online]. Retrieved from the Internet: <URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3032230>, (2010), 52-59.
[cited by applicant]
Hayreh, Sohan Singh, “Cerebrospinal fluid pressure and glaucomatous optic disc cupping (response to Berdahl and colleagues)”, Graefes Arch Clin Exp Opthtalmol, 247, (2009), 1291-1294.
[cited by applicant]
Hillen, Mark, “In Practice (Viip: A Space Odyssey)”, The Ophthalmologist , vol. 11, (Sep. 2014), 6 pgs.
[cited by applicant]
Jonas, Jost B., et al., “Anatomic Relationship between Lamina Cribosa, Intraocular Space, and Cerebrospinal Fluid Space”, Investigative Ophthalmology & Visual Science, vol. 44, No. 12, (Dec. 2003), 5189-5195.
[cited by applicant]
Jung, Jong Jin, et al., “Analysis of the Causes of Optic-Disc Swelling”, Korean J Ophthalmol, 25 (1), (2011), 33-36.
[cited by applicant]
Kent, Christopher, “Iop: Managing the Fluctuation Factor”, Review of Ophthalmology, [Online]. Retrieved from the Internet: <URL: http://www.reviewofophthalmology.com/content/i/1533/c/28662/dnnprintmode/true/?skinsrc=[ I…
[cited by applicant]
Morgan, William H., et al., “Retinal venous pulsation: Expanding our understanding and use of this enigmatic phenomenon”, Progress in Retinal and Eye Research xxx, (2016), 1-26.
[cited by applicant]
Morgan, William H, et al., “The Correlation between Cerebrospinal Fluid Pressure and Retrolaminar Tissue Pressure”, IOVS, Jul. 1998, vol. 39, No. 8, (Jul. 1998), 10 pgs.
[cited by applicant]
Wostyn, Peter, et al., “Glaucoma and the Role of Cerebrospinal Fluid Dynamics”, Investigative Ophthalmology & Visual Sciences, (2015), 6630.
[cited by applicant]
Yeoh, Ronald, “Hydrorupture of the posterior capsule in femtosecond-laser cataract surgery”, J Cataract Refract Surg, vol. 38, (Apr. 2012), 730-731.
[cited by applicant]
Young, Joshua, “ASFH CSF Pressure and Glaucoma (Guest: John P. Berdahl, M.D.)”, As Seen From Here: 198 (Podcast—iTunes) (Transcribed) Run time: 15:14 Minutes, (Jul. 8, 2008), 5 pgs.
[cited by applicant]
Zhang, Zheng, et al., “Glaucoma and the Role of Cerebrospinal Fluid Dynamics”, Investigative Ophthalmology & Visual Sciences, (2015), 6632.
[cited by applicant]
“Chinese Application Serial No. 202111044223.4, Office Action mailed Jun. 29, 2023”, W English Translation, 26 pgs.
[cited by applicant]
“Brazilian Application Serial No. 1120180038385, Opinion for non-patenteability (RPI 7.1) mailed Aug. 8, 2023”, w English Translation, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 18/538,603, Non Final Office Action mailed Feb. 18, 2025”, 14 pgs.
[cited by applicant]
“U.S. Appl. No. 18/538,603, Response filed May 19, 2025 to Non Final Office Action mailed Feb. 18, 2025”, 10 pgs.
[cited by applicant]
“Japanese Application Serial No. 2024-025289, Decision of Rejection mailed May 7, 2025”, w/ English Translation, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 12/380,239, Final Office Action mailed Oct. 8, 2014”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 12/380,239, Response filed Jan. 7, 2015 to Final Office Action mailed Oct. 8, 2014”, 20 pgs.
[cited by applicant]
“U.S. Appl. No. 12/380,239, Non Final Office Action mailed Feb. 6, 2015”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 12/380,239, Response filed May 4, 2015 to Non Final Office Action mailed Feb. 6, 2015”, 13 pgs.
[cited by applicant]
“U.S. Appl. No. 12/380,239, Notice of Allowance mailed Jun. 19, 2015”, 5 pgs.
[cited by applicant]
“U.S. Appl. No. 12/380,239, Restriction Requirement mailed Jun. 2, 2011”, 5 pgs.
[cited by applicant]
“U.S. Appl. No. 12/380,239, Response filed Jul. 1, 2011 to Restriction Requirement mailed Jun. 2, 2011”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 12/380,239, Non Final Office Action mailed Jul. 14, 2011”, 15 pgs.
[cited by applicant]
“U.S. Appl. No. 12/380,239, Response filed Oct. 12, 2012 to Non Final Office Action mailed Jul. 14, 2011”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 12/380,239, Response filed Apr. 16, 2014 to Non Final Office Action mailed Jul. 14, 2011”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 12/380,239, Amendment filed May 8, 2014”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 12/380,239, Notice of Non-Compliant Amendment mailed Jun. 20, 2014”, 2 pgs.
[cited by applicant]
“U.S. Appl. No. 12/380,239, Response to Notice of Non-Compliant Amendment mailed Jun. 24, 2014”, 14 pgs.
[cited by applicant]
“U.S. Appl. No. 12/380,239, Corrected Notice of Allowance mailed Jul. 8, 2015”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 14/877,499, Preliminary Amendment filed Oct. 8, 2015”, 5 pgs.
[cited by applicant]
“EyeGatell Transcription”, youtube, [Online]. Retrieved from the Internet: URL: https: www.youtube.com watch?v=v7oSLe-bLWo, (Accessed Nov. 3, 2017), 1 pg.
[cited by applicant]
“U.S. Appl. No. 14/877,499, Non Final Office Action mailed Nov. 27, 2017”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 14/877,499, Response filed Feb. 14, 2018 to Non Final Office Action mailed Nov. 27, 2017”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 14/877,499, Notice of Allowance mailed Mar. 30, 2018”, 5 pgs.
[cited by applicant]
“International Application Serial No. PCT US2019 045767, International Search Report mailed Nov. 26, 2019”, 5 pgs.
[cited by applicant]
“International Application Serial No. PCT US2019 045767, Written Opinion mailed Nov. 26, 2019”, 7 pgs.
[cited by applicant]
“International Application Serial No. PCT US2019 045767, Intemational Preliminary Report on Patentability mailed Feb. 18, 2021”, 7 pgs.
[cited by applicant]
“Chinese Application Serial No. 201680056279.2, Response filed Jun. 7, 2021 to Office Action mailed Feb. 19, 2021”, w English claims, 28 pgs.
[cited by applicant]
“Indian Applicaiton Serial No. 201817010073, Response filed Jun. 7, 2021 to First Examination Report mailed Dec. 11, 2020”, 138 pgs.
[cited by applicant]
“European Application Serial No. 16763632.3, Communication Pursuant to Article 94(3) EPC mailed Jun. 17, 2021”, 4 pgs.
[cited by applicant]
“Australian Application Serial No. 2019319942, First Examination Report mailed Aug. 9, 2021”, 3 pgs.
[cited by applicant]
“Eurasian Application Serial No. 19759175.3, Response to Communication pursuant to Rules 161(1) and 162 EPC filed Sep. 13, 2021”, 16 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Response filed Nov. 22, 2021 to Non Final Office Action mailed May 25, 2021”, 8 pgs.
[cited by applicant]
“European Application Serial No. 16763632.3, Response filed Dec. 27, 2021 to Communication Pursuant to Article 94(3) EPC mailed Jun. 17, 2021”, 14 pgs.
[cited by applicant]
“Indian Application Serial No. 202117009018, First Examination Report mailed Jan. 24, 2022”, 7 pgs.
[cited by applicant]
“Canadian Application Serial No. 3,109,225, Office Action mailed Feb. 10, 2022”, 5 pgs.
[cited by applicant]
“Indian Application Serial No. 202117009018, Response filed Mar. 16, 2022 to First Examination Report mailed Jan. 24, 2022”, w English claims, 110 pgs.
[cited by applicant]
“Australian Application Serial No. 2019319942, Response filed Apr. 22, 2022 to First Examination Report mailed Aug. 9, 2021”, 163 pgs.
[cited by applicant]
“Japanese Application Serial No. 2021-505948, Notification of Reasons for Refusal mailed May 10, 2022”, w English translation, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Response filed May 31, 2022 to Final Office Action mailed Mar. 30, 2022”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 17/168,670, Preliminary Amendment filed Jun. 9, 2022”, 5 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Advisory Action mailed Jun. 14, 2022”, 5 pgs.
[cited by applicant]
“Canadian Application Serial No. 3,109,225, Response Filed Jun. 10, 2022 to Office Action mailed Feb. 10, 2022”, 36 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Response to Advisory Action mailed Jun. 14, 2022 and Final Office Action mailed Mar. 30, 2022”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Response filed Jun. 29, 2022 to Advisory Action mailed Jun. 14, 2022”, 9 pgs.
[cited by applicant]
“Japanese Application Serial No. 2021-128035, Notification of Reasons for Rejection mailed Jul. 5, 2022”, w English Translation, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Notice of Allowance mailed Jul. 22, 22”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Corrected Notice of Allowability mailed Aug. 3, 2022”, 5 pgs.
[cited by applicant]
Araci, Ismail E., “An implantable microfluidic device for self-monitoring of intraocular pressure”, Nature Medicine, vol. 20, No. 9, (Sep. 2014), 1074-1080.
[cited by applicant]
Berdahl, J. P., “Intracranial pressure and glaucoma”, Curr Opin Ophthalmol (2), (Mar. 2010), 1 pg.
[cited by applicant]
Chowdhury, “Intracranial Pressure and Its Relationship to Glaucoma: Current Understanding and Future Directions”, Med Hypothesis Discov Innov Ophthalmol, 4(3), (2015), 1 pg.
[cited by applicant]
Kent, Christopher, “IOP: Managing the Fluctuation Factor”, Review of Ophthamology, (Nov. 21, 2015), 6 pgs.
[cited by applicant]
Kwon, “A Patient's Guide to Glaucoma”, sections 5A and 6B, (2006), 4 pgs.
[cited by applicant]
Lehman, “Experimental effect of intracranial hypertension upon intraocular pressure”, J Neurosurg, 36(1):60-6, (Jan. 1972), 1 pg.
[cited by applicant]